[go: up one dir, main page]

MX2020002262A - Agonistas selectivos de rar en combinacion con moduladores inmunitarios para inmunoterapia contra el cancer. - Google Patents

Agonistas selectivos de rar en combinacion con moduladores inmunitarios para inmunoterapia contra el cancer.

Info

Publication number
MX2020002262A
MX2020002262A MX2020002262A MX2020002262A MX2020002262A MX 2020002262 A MX2020002262 A MX 2020002262A MX 2020002262 A MX2020002262 A MX 2020002262A MX 2020002262 A MX2020002262 A MX 2020002262A MX 2020002262 A MX2020002262 A MX 2020002262A
Authority
MX
Mexico
Prior art keywords
combination
cancer immunotherapy
immune modulators
rar agonists
selective rar
Prior art date
Application number
MX2020002262A
Other languages
English (en)
Inventor
Martin E Sanders
Roshantha A Chandraratna
Original Assignee
Io Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Therapeutics Inc filed Critical Io Therapeutics Inc
Publication of MX2020002262A publication Critical patent/MX2020002262A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen métodos para tratar el cáncer que comprende administrar células inmunitarias con CAR modificado y al menos un agonista del receptor del ácido retinoico.
MX2020002262A 2017-08-31 2018-08-30 Agonistas selectivos de rar en combinacion con moduladores inmunitarios para inmunoterapia contra el cancer. MX2020002262A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762552814P 2017-08-31 2017-08-31
PCT/US2018/048876 WO2019046591A1 (en) 2017-08-31 2018-08-30 SELECTIVE RAR AGONISTS IN ASSOCIATION WITH IMMUNE MODULATORS IN ANTICANCER IMMUNOTHERAPY

Publications (1)

Publication Number Publication Date
MX2020002262A true MX2020002262A (es) 2020-07-20

Family

ID=65436409

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002262A MX2020002262A (es) 2017-08-31 2018-08-30 Agonistas selectivos de rar en combinacion con moduladores inmunitarios para inmunoterapia contra el cancer.

Country Status (13)

Country Link
US (5) US10363272B2 (es)
EP (1) EP3675843A4 (es)
JP (1) JP2020532537A (es)
KR (1) KR20200044889A (es)
CN (1) CN111148514A (es)
AU (1) AU2018326617B2 (es)
CA (1) CA3073953A1 (es)
IL (1) IL272971A (es)
MX (1) MX2020002262A (es)
NZ (1) NZ761401A (es)
SG (1) SG11202001479RA (es)
WO (1) WO2019046591A1 (es)
ZA (1) ZA202001884B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316583A (zh) 2005-09-30 2008-12-03 生命医药公司 用特异性rxr激动剂治疗癌症
WO2013090616A1 (en) 2011-12-13 2013-06-20 Io Therapeutics, Inc. Autoimmune disorder treatment using rxr agonists
US10092535B2 (en) 2015-10-31 2018-10-09 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
PL3426303T3 (pl) 2016-03-10 2022-10-03 Io Therapeutics, Inc. Leczenie zaburzeń mięśniowych za pomocą kombinacji agonistów rxr i hormonów tarczycy
SG11201807255YA (en) 2016-03-10 2018-09-27 Io Therapeutics Inc Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
CN110958881A (zh) 2017-07-13 2020-04-03 Io治疗公司 与免疫调节剂联合应用于癌症免疫治疗的免疫调节性类视黄醇和rexinoid化合物
MX2020002262A (es) 2017-08-31 2020-07-20 Io Therapeutics Inc Agonistas selectivos de rar en combinacion con moduladores inmunitarios para inmunoterapia contra el cancer.
WO2019060600A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
CN112390731B (zh) * 2020-11-16 2022-11-25 成都大学 一种具有多靶点的维甲酸类衍生物及其制备方法与应用
WO2023108015A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers
CN119451672A (zh) * 2022-06-27 2025-02-14 Io治疗公司 四氢萘酚的合成及其用途
KR20240064351A (ko) 2022-11-04 2024-05-13 한국원자력연구원 무정전 전원을 갖는 환경방사선 감시시스템의 전원 시스템 및 그 방법

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1576007A (en) 1976-02-11 1980-10-01 Beecham Group Ltd Hypolipidaemic compositions
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
US5234926A (en) 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5324840A (en) 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
WO1994014777A1 (en) 1992-12-28 1994-07-07 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
CA2138000A1 (en) 1994-01-03 1995-07-04 John E. Starrett, Jr. Retinoid-like compounds
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6942980B1 (en) 1995-09-01 2005-09-13 Allergan, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
FR2739557B1 (fr) 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5723666A (en) 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
ATE236654T1 (de) 1996-08-28 2003-04-15 Inst Nat Sante Rech Med Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
US5739338A (en) 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
DE60016404T2 (de) 1999-06-11 2005-10-27 Allergan, Inc., Irvine Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren
AU6228000A (en) 1999-07-23 2001-02-13 Allergan Sales, Inc. The use of retinoid receptor antagonists in the treatment of prostate carcinoma
TWI281911B (en) * 2000-04-04 2007-06-01 Allergan Inc Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
PT1324970E (pt) 2000-10-02 2009-01-02 Hoffmann La Roche Novos retinóides para o tratamento de enfisema
EP1353217A1 (en) 2002-03-29 2003-10-15 JSR Corporation Optical alignment method and liquid crystal display element
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2005046726A2 (en) 2003-11-12 2005-05-26 Allergan, Inc. Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist
US7476673B2 (en) 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
EP1799812A4 (en) * 2004-09-16 2009-09-09 Gamida Cell Ltd EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS
CN101316583A (zh) 2005-09-30 2008-12-03 生命医药公司 用特异性rxr激动剂治疗癌症
CN101472572B (zh) 2006-05-16 2012-10-10 Io治疗有限责任公司 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
WO2008121570A1 (en) 2007-03-29 2008-10-09 Irm Llc Compounds and methods for modulating g protein-coupled receptors
AR069747A1 (es) * 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
SI2594590T1 (sl) * 2007-12-14 2015-03-31 Bristol-Myers Squibb Company Postopek za izdelavo vezavnih molekul za humani receptor OX40
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2011155607A1 (ja) * 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
US9446105B2 (en) * 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
WO2014160627A1 (en) * 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
WO2014163684A1 (en) 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
PT2992017T (pt) 2013-05-02 2021-01-29 Anaptysbio Inc Anticorpos dirigidos contra a morte programada 1 (pd-1)
MY186311A (en) 2013-12-20 2021-07-08 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
ME03558B (me) * 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
JP2017513942A (ja) 2014-04-11 2017-06-01 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Ｍｅｒｔｋ特異的ピロロピリミジン化合物
EP3195168B1 (en) 2014-07-31 2022-09-07 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
KR20170045237A (ko) 2014-09-08 2017-04-26 셀진 코포레이션 항-pd1 또는 항-pdl1 단클론성 항체와 조합된 시티딘 유사체의 경구 제제를 사용한 질환 또는 장애를 치료하는 방법
CN107001478B (zh) * 2014-10-14 2022-01-11 诺华股份有限公司 针对pd-l1的抗体分子及其用途
KR102588853B1 (ko) 2014-12-25 2023-10-16 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 T 세포 집단의 개변 방법
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
WO2016144976A1 (en) * 2015-03-09 2016-09-15 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
WO2016196237A1 (en) * 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
CN119564879A (zh) 2015-08-18 2025-03-07 乐天医药生技股份有限公司 用于光免疫疗法的组合物、联用及相关方法
PE20181322A1 (es) * 2015-09-01 2018-08-14 Agenus Inc Anticuerpo anti-pd1 y sus metodos de uso
EA201890996A1 (ru) 2015-10-20 2018-10-31 Кайт Фарма, Инк. Способ получения t-клеток для т-клеточной терапии
EP3957304A1 (en) * 2015-11-25 2022-02-23 IO Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
CN108925136B (zh) * 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
WO2017201200A1 (en) 2016-05-19 2017-11-23 Orphagen Pharmaceuticals, Inc. Therapeutic compositions containing rar-alpha antagonists
SG11201810951RA (en) 2016-06-10 2019-01-30 Io Therapeutics Inc Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
CN110958881A (zh) * 2017-07-13 2020-04-03 Io治疗公司 与免疫调节剂联合应用于癌症免疫治疗的免疫调节性类视黄醇和rexinoid化合物
MX2020002262A (es) 2017-08-31 2020-07-20 Io Therapeutics Inc Agonistas selectivos de rar en combinacion con moduladores inmunitarios para inmunoterapia contra el cancer.

Also Published As

Publication number Publication date
JP2020532537A (ja) 2020-11-12
EP3675843A1 (en) 2020-07-08
EP3675843A4 (en) 2021-11-03
US20200138867A1 (en) 2020-05-07
CN111148514A (zh) 2020-05-12
NZ761401A (en) 2022-11-25
US10532073B2 (en) 2020-01-14
SG11202001479RA (en) 2020-03-30
CA3073953A1 (en) 2019-03-07
US20190060362A1 (en) 2019-02-28
US20210100844A1 (en) 2021-04-08
US20190343883A1 (en) 2019-11-14
US20190314415A1 (en) 2019-10-17
AU2018326617A1 (en) 2020-02-27
IL272971A (en) 2020-04-30
AU2018326617B2 (en) 2022-12-01
US10532074B2 (en) 2020-01-14
US11786555B2 (en) 2023-10-17
KR20200044889A (ko) 2020-04-29
US10874694B2 (en) 2020-12-29
US10363272B2 (en) 2019-07-30
ZA202001884B (en) 2021-10-27
WO2019046591A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
MX2020002262A (es) Agonistas selectivos de rar en combinacion con moduladores inmunitarios para inmunoterapia contra el cancer.
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
MX2017003645A (es) Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
CO2018004132A2 (es) Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer
BR112019011138A2 (pt) composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos
CL2018002828A1 (es) Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores.
CL2020001452A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados de este.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
CO2019008946A2 (es) Anticuerpos anti-tgf-beta y su uso
MX2020000467A (es) Compuestos retinoides y rexinoides inmunomoduladores en combinacion con inmunomoduladores para inmunoterapia contra cancer.
MX2017005553A (es) Terapia de combinacion para cancer.
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
MX2021009926A (es) Agonistas il-2rbeta-selectivos en combinacion con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.
MX2017004634A (es) Composiciones y metodos para inhibir la expresion del gen de hidroxiacido-oxidasa 1 (glicolato-oxidasa) (hao1).
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
MX2016010080A (es) Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer.
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
PE20171135A1 (es) Metodos para seleccionar una linea de celulas t y donador de la misma para terapia celular adoptiva
MX2015010312A (es) Metodos para tratamiento del melanoma.
MX2019013621A (es) Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.
MX2017007256A (es) Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer.